SET2 is a Selective TRPV2 Antagonist

TRP Channel (Transient receptor potential channel) is a group of ion channels located mostly on the plasma membrane of numerous human and animal cell types. There are about 28 TRP channels that share some structural similarities toSET2 - SET2 is a Selective TRPV2 Antagonist

each other. These are grouped into two broad groups: Group 1 includes TRPC, TRPV, TRPM, TRPN, and TRPA. In group 2, there are TRPP and TRPML. Many of these channels mediate a variety of sensations like the sensations of pain, hotness, warmth or coldness, different kinds of tastes, pressure, and vision. TRP channels are relatively non-selectively permeable to cations, including sodium, calcium and magnesium. Transient receptor potential (TRP) channels play significant roles in human physiology and facilitate the permeation of essential ions (Na+, Ca2+) through the plasma membrane.

TRPV2 is a Ca2+-permeable non-selective cation channel belonging to the vanilloid subfamily of the TRP channels. TRPV2 plays a significant role in maintaining physiological cardiomyocyte function, with potential therapeutic use of TRPV2 blockade in cardiomyopathy. Meanwhile, TRPV2 plays a role in phagocytosis in macrophages, placental development, T-cell activation, and insulin secretion in pancreatic β-cells. Moreover, TRPV2 plays a significant role in the progression, drug resistance and metastasis of different forms of cancer.

SET2 is a selective TRPV2 antagonist. SET2 blocks the TRP channel and suppresses prostate cancer cells migration. Meanwhile, SET2 reduces the lysophosphatidic acid-induced cytoplasmic calcium increases. In vitro, SET2 abrogates the migration of PC-3M cells expressing TRPV2. Besides, SET2 can inhibit 2-APB-evoked current in HEK293T cells transiently co-transfected with TRPV2 and LPAR1. What’s more, SET2 inhibits the increase of LPA-induced cytoplasmic calcium and LPA-induced migration in PC-3M cells.

All in all, SET2 is a selective TRPV2 antagonist. SET2 can block the TRP channel and suppresse prostate cancer cells migration.